首页> 外文OA文献 >P508 Evaluation of the diagnostic performance of two commercially available tests for infliximab trough levels (IFX-TL) and antibodies to infliximab (ATI) titration in inflammatory bowel disease (IBD)

【2h】

P508 Evaluation of the diagnostic performance of two commercially available tests for infliximab trough levels (IFX-TL) and antibodies to infliximab (ATI) titration in inflammatory bowel disease (IBD)

机译：P508评估两种商业上可获得的两种商业上可获得的测试的诊断性能（IFX-T1）和炎症性肠病（IBD）中的英夫利昔单抗（ATI）滴定的抗体（IBD）

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
M. Daperno; F. Frigerio; C. Guiotto; L. Germano; E. Ercole; S. Aricò; M. Fracchia; C. Rigazio; A. Lavagna; R. Pellerito; M. Migliardi; R. Rocca;
展开▼
作者单位

展开▼
年度 2013
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Monitoring of infliximab trough levels and anti-infliximab antibodies in inflammatory bowel diseases: A comparison of three commercially available ELISA kits [J] . Bertin Daniel, Serrero Melanie, Grimaud Jean Charles, Cytokine . 2020,第期

机译：监测炎症性肠疾病中英夫利昔单抗水平和抗英夫利昔单抗抗体：三种市售ELISA试剂盒的比较
2. Clinical relevance and inter-test reliability of anti-infliximab antibodies and infliximab trough levels in patients with inflammatory bowel disease [J] . Guiotto Cristina, Daperno Marco, Frigeri Francesco, Digestive and liver disease: official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver . 2016,第2期

机译：炎性肠病患者抗英夫利昔单抗抗体和英夫利昔单抗谷水平的临床相关性和测试间可靠性
3. Combination of C-reactive Protein, Infliximab Trough Levels, and Stable but Not Transient Antibodies to Infliximab Are Associated With Loss of Response to Infliximab in Inflammatory Bowel Disease [J] . Roblin X., Marotte H., Leclerc M., Journal of Crohn’s & colitis . 2015,第7期

机译：C反应蛋白，英夫利昔单抗谷水平和稳定但不是暂时性抗体对英夫利昔单抗的组合与炎症性肠病中对英夫利昔单抗的反应丧失有关
4. Indications for use of infliximab in inflammatory bowel disease [C] . G. ROGLE Falk Symposium . 2007

机译：用于炎症性肠病infliximab的适应症
5. Serum and Fecal Biomarkers Predict Response to Infliximab Therapy in Pediatric Patients with Inflammatory Bowel Disease [D] . Kim, Jochebed. 2020

机译：血清和粪便生物标志物预测对炎症肠病小儿患者的英夫利昔单抗疗法的反应
6. Impact of Antibodies to Infliximab on Clinical Outcomes and Serum Infliximab Levels in Patients With Inflammatory Bowel Disease (IBD): A Meta-Analysis [O] . Kavinderjit S. Nanda, Adam S. Cheifetz, Alan C. Moss -1

机译：抗体的影响英夫利昔单抗对患者临床结果和英利昔单抗血清水平炎症性肠病（IBD）的meta分析
7. P569 Clinical correlations of infliximab trough levels (IFX-TL) and antibodies to infliximab (ATI) in inflammatory bowel disease [O] . M. Daperno, A. Lavagna, M. Fracchia, 2013

机译：P569富胎突槽水平（IFX-T1）和抗生素（ATI）在炎性肠病中的临床相关性

P508 Evaluation of the diagnostic performance of two commercially available tests for infliximab trough levels (IFX-TL) and antibodies to infliximab (ATI) titration in inflammatory bowel disease (IBD)

著录项

引文网络

相似文献

相关主题

期刊订阅